Volume 14, Number 5—May 2008
Perspective
Scale-up of Multidrug-Resistant Tuberculosis Laboratory Services, Peru
Sonya S. Shin*
, Martin Yagui†, Luis Ascencios†, Gloria Yale‡, Carmen Suarez‡, Neyda Quispe†, Cesar Bonilla‡, Joaquin Blaya§, Allison Taylor¶, Carmen Contreras#, and Peter Cegielski¶
, Martin Yagui†, Luis Ascencios†, Gloria Yale‡, Carmen Suarez‡, Neyda Quispe†, Cesar Bonilla‡, Joaquin Blaya§, Allison Taylor¶, Carmen Contreras#, and Peter Cegielski¶
Table 1
HIV and tuberculosis (TB), Peru, 2005*
| Characteristic | Value |
|---|---|
| Total population | 28,300,000 |
| Population in Lima | 7,300,000 |
| Average life expectancy, y | 69 |
| Infant mortality rate | 31/100,000 live births |
| GDP per capita | $2,500 |
| Population living in poverty | 54% |
| National HIV prevalence | 0.6% |
| Estimated no. HIV positive | 60,000–80,000 |
| No. receiving HIV therapy | 9,157 |
| TB incidence | 108/100,000 |
| MDR TB in new patients | 3% |
| MDR TB in previously treated patients | 12.3% |
| TB in HIV patients | ≈30% |
| HIV in TB patients | ≈3% |
| MDR TB in co-infected patients | 30%–47% |
| Mortality rate among co-infected patients† | <38% |
| Mortality rate among MDR TB–HIV patients | <57% |
*GDP, gross domestic product; MDR TB, multidrug-resistant TB.
†Co-infected with HIV and TB but not necessarily MDR-TB.
Page created: July 08, 2010
Page updated: July 08, 2010
Page reviewed: July 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.